An interventional study of fermented papaya preparation in Anemia and Chronic Kidney Disease Stage 5, sponsored by Hadassah Medical Organization. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-19.
Sponsored by Hadassah Medical Organization · Not applicable, Interventional, and Treatment
Fermented papaya preparation has been reported to bind and neutralize reactive oxygen species as well as iron. Patients undergoing hemodialysis are generally on iron overload status due to their inability to use iron storage adequately. The aim of this study is to evaluate the effect of FPP on the iron status of these patients.
Background and rationale
Patients with chronic kidney disease (CKD) on hemodialysis often suffer from anemia. The anemia is primarily caused by insufficient production by the failing kidneys of the erythroid stimulating hormone - erythropoietin (Epo). Oxidative stress may be another reason for anemia. Oxidative stress in RBCs of these patients may be caused by:
Iron overload - In order to maximize the effect of Epo, the treatment is supplemented by IV injection of iron. This iron may accumulate and cause iron overload in some hemodialyzed patients. Under normal conditions, iron is transported in the blood and enters into cells following binding the plasma protein transferrin. However, when iron content in the plasma exceeds the binding capacity of transferrin, non-transferrin-bound iron (NTBI) appears. This iron enters cells via alternative pathways, and accumulates in the cytosol, where it participates in chemical reactions (Haber-Weiss, Fenton) that generate reactive oxygen species (ROS). Excess ROS overcomes the protective cellular anti-oxidant mechanisms and becomes cytotoxic. In the erythroid system, excess ROS causes accelerated apoptosis (programmed cell death) of precursor cells in the bone marrow and a short survival of mature RBCs in the circulation, resulting in chronic anemia. Excess iron and ROS may also damage other cells and lead to malfunctioning of vital organs, such as the heart and liver (2,3).
FPP has been reported to bind and neutralize (scavenge) ROS (4) as well as free iron (chelate) (5). Both activities ameliorate the oxidative stress.
Treatment with FPP of various diseases associated with oxidative stress, administered orally (3 gr. X 3 times a day), have been shown to significantly ameliorate the symptoms underlying these diseases (6-18). FPP has a long track-record of safe human consumption (19-20). It has been used for many years as a food-supplement by thousands of people around the world without any reported side effect.
Research goals
To study the effect of fermented papaya preparation (FPP) on patients with chronic kidney disease (CKD) under dialysis, receiving intravenous iron.
General Protocol:
This will be a single-arm, open-label, single-center study in 20 patients upon dialysis receiving IV iron supplementation. All participants will be treated with FPP for 3 months.
Bi-weekly, blood samples will be drawn and the patients will be monitored for assessment of safety and efficacy.
Detailed Protocol Twenty patients, treated on Hadassah Medical center, Jerusalem, will be screened and recruited according to clinical criteria.
inclusion criteria: Age 18-70. Any primary kidney disease resulting in ESRD. Hemodynamically stable status. PTH up to 2-9 times upper normal limits. Patients receiving ESA may be included.
Any evidence of acute bleeding. Hg level of less than 8 g/dL Patients with known allergy to Papaya
3. Patients will be treated orally with FPP (3 gr. X 3 times a day) for 3 months.
4. Blood samples will be obtained from all patients prior and during (every 2 weeks) treatment.
5. Samples will be analyzed for:
Blood chemistry for Potassium, Albumin and Phosphorous (every 2 weeks).
Anemia: Complete blood count, including RBC number and indexes, as well as hemoglobin content.
Oxidative stress: (once monthly) Reactive oxygen species Reduced glutathione Membrane lipid peroxidation External phosphatidylserine
Iron overload: (once monthly) Serum ferritin Serum transferin. Labile plasma iron Serum hepcidin Intracellular labile iron pool
Safety measures:
Adverse events: Frequency, severity, seriousness, time to onset, duration, and relatedness to study product.
1,768 studies on the registry are indexed under Anemia; 244 are open to participants now.
This study's planned enrollment of 20 is below the median of 96 across 1,318 interventional studies indexed under Anemia.
Browse Anemia studies →Hadassah Medical Organization is the lead sponsor of 674 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
active treatment with fermented papaya preparation
Dietary Supplement: fermented papaya preparation
dietary supplementation with fermented papaya preparation
Also known as: FPP
Iron status
evaluation of iron overload reduction after 3 months of treatment with fermented papaya preparation
Time frame: 3 months of treatment
No study locations are listed for this record.
Plan to share: No
This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fermented papaya preparation
Hadassah Medical Organization →